Adherence to antiretroviral therapy among HIV-infected methadone patients: Effect of ongoing illicit drug use

American Journal of Drug and Alcohol Abuse

Volumn 26, Issue 2, 2000, Pages 195-205

  Stein, Michael D ^a,b   Rich, Josiah D ^a   Maksad, Jina ^a   Chen, Mei Hsiu ^a   Hu, Ping ^a   Sobota, Mindy ^a   Clarke, Jennifer ^a  

^a BROWN UNIVERSITY   (United States)

^b RHODE ISLAND HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; DELAVIRDINE; ILLICIT DRUG; INDINAVIR; METHADONE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; VIRUS RNA; ZIDOVUDINE;

ARTICLE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; DAILY LIFE ACTIVITY; DISEASE ASSOCIATION; DRUG TRAFFIC; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; MALE; METHADONE TREATMENT; PATIENT COMPLIANCE; RNA ANALYSIS;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COMORBIDITY; HIV INFECTIONS; HIV PROTEASE INHIBITORS; METHADONE; OPIOID-RELATED DISORDERS; PATIENT COMPLIANCE;

EID: 0034123094     PISSN: 00952990     EISSN: None     Source Type: Journal    
DOI: 10.1081/ADA-100100600     Document Type: Article

References (25)

1. Gulick, R. M., Mellors, J. W., Havlir, D., et al., Treatment with indinavir, zidovudine, and lamivudine in adults with HIV infection and prior antiretroviral therapy, N. Engl. J. Med. 337: 734-739 (1997).
2. Palella, F. J., Delaney, K. M., Moorman, A. C., et al., Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection, N. Engl. J. Med. 338:853-860 (1998).
3. Carpenter, C. C. J., Fischl, M. A., Hammer, S. M., et al., Antiretroviral therapy for HIV infection in 1997: update recommendations of the International AIDS Society-USA panel, JAMA 277: 1962-1969 (1997).
4. Torres, R. A., and Barr, M., Impact of combination therapy for HIV infection on inpatient census, N. Engl. J. Med. 336:1531-1532 (1997).
5. Wainberg, M. A., and Friedland, G., Public health implications of antiretroviral therapy and HIV drug resistance, JAMA 279:1977-1983 (1998).
6. Ickovics, J., and Meisler, A. W., Adherence in AIDS clinical trials: a framework for clinical research and clinical care, J. Clin. Epidemiol. 50:385-391 (1997).
7. Samet, J. H., Libman, H., Steger, K. A., et al., Compliance with zidovudine therapy in patients infected with human immunodeficiency virus type 1: a cross-sectional study in a municipal hospital clinic, Am. J. Med. 92:495-502 (1992).
8. Holmberg SD, The estimated prevalence and incidence of HIV in 96 large U.S. metropolitan areas, Am. J. Public Health 86:642-654 (1996).
9. Herman, M., and Gourevitch, M. N., Integrating primary care and methadone maintenance treatment: implementation issues, J. Addict. Dis. 16:91-102 (1997).
10. Samet, J. H., Stein, M. D., and O'Connor, P. G., Models of medical care for HIV-infected drug users, Substance Abuse 16:131-139 (1995).
11. O'Connor, P. G., Molde, S., Henry, S., et al., Human immunodeficiency virus infection in intravenous drug users: a model for primary care, Am. J. Med. 93:382-386 (1992).
12. Selwyn, P. A., Budner, N. S., Wasserman, W. C., et al., Utilization of on-site primary care services by HIV-seropositive and seronegative drug users in a methadone maintenance program, Public Health Rep. 108:492-500 (1993).
13. Sorenson, J. L., Batki, S. L., Good, P., et al., Methadone maintenance program for AIDS-affected opiate addicts, J. Substance Abuse Treat. 6:87-94 (1989).
14. Selwyn, P. A., Feingold, A. R., Iezza, A., et al., Primary care for patients with human immunodeficiency virus (HIV) in a methadone maintenance treatment program, Ann. Int. Med. 111:761-763 (1989).
15. Wall, T. L., Sorenson, J. L., Batki, S. L., et al., Adherence to zidovudine (AZT) among HIV-infected methadone patients: a pilot study of supervised therapy and dispensing compared to usual care, Drug Alcohol Depend. 37:261-269 (1995).
16. Umbricht-Schneiter, A., Ginn, D. H., Pabst, K. M., et al., Providing medical care to methadone clinic patients: referrals versus on-site care, Am. J. Public Health 84:207-210 (1994).
17. Gallo, D., George, J. R., Fitchen, J. H., et al., Evaluation of a system using oral mucosal transudate for HIV-1 antibody screening and confirmatory testing, JAMA 277:254-258 (1997).
18. Lerner, B. H., Gulick, R. M., and Bubler, N. N., Rethinking nonadherence: historical perspective on triple-drug therapy for HIV disease, Ann. Int. Med. 129:573-578 (1998).
19. Eldred, L. J., Wu, A. W., Chaisson, R. E., et al., Adherence to antiretroviral and pneumocystis prophylaxis in HIV disease, J. Acquir. Immunodefic. Syndr. Hum. Retrovirol. 18:117-125 (1998).
20. Stone, V. E., Clarke, J., Lovell, J., et al., HIV/AIDS patients' perspectives on taking and adhering to protease inhibitor containing regimens, J. Gen. Int. Med. 13:586-593 (1998).
21. Samuels, J. E., Hendrix, J., Hilton, M., et al., Zidovudine therapy in an inner city population, J. Acquir. Immunodefic. Syndr. Hum. Retrovirol. 3:877-883 (1990).
22. Broers, B., Morabia, A., and Hirschel, B., A cohort study of drug users' compliance with zidovudine treatment, Arch. Int. Med. 154:1121-1127 (1994).
23. Cramer, J. A., Mattson, J. H., Prevey, M. L., et al., How often is medication taken as prescribed? A novel assessment technique, JAMA 261:3273-3277 (1989).
24. Sherer, R., Adherence and antiretroviral therapy in injection drug users, JAMA 280:567-568 (1998).
25. Singh, N., Squier, C., Sivek, C., et al., Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: a prospective assessment with implications for enhancing compliance, AIDS Care 8:261-269 (1996).